GHK-Cu and Hair Research: What the Follicle Studies Show

The reference behind nearly every copper-peptide hair claim is a 2007 organ-culture study, meaning small pieces of living tissue kept alive and studied outside the body, using scalp hair follicles and dermal papilla cells (the cells at the base of a follicle that help control hair growth) obtained from ten healthy volunteers under informed consent. Follicles were cultured for twelve days across concentrations from 10⁻¹³ to 10⁻⁷ M, with 240 follicles from three volunteers analysed, thirty per condition. [1]

Follicle organ culture works by carefully dissecting individual hair follicles out of donated scalp tissue and keeping them alive in a nutrient medium, where they will continue to grow the hair shaft for a limited number of days, generally with the follicle's internal architecture, including the dermal papilla at its base, intact. This makes it a considerably richer model than a single layer of cells in a dish, because it preserves the interactions between different cell types inside the follicle. It is still an isolated piece of tissue with no blood supply, no immune system, and no connection to the hormonal signals, such as androgens, known to regulate hair growth in a living scalp.

ANIMAL/EX VIVO HUMAN TISSUE

The compound tested in that study was AHK-Cu, an alanine-containing variant of the copper tripeptide, not GHK-Cu. Sources that present this work as GHK-Cu hair evidence are substituting one molecule for another. [1]

Dermal papilla cell proliferation (an increase in the number of these cells) rose significantly across the same 10⁻¹² to 10⁻⁹ M window and showed no effect at 10⁻⁸ M. A reduction in apoptotic dermal papilla cells (cells undergoing a normal programmed self-destruction process) at 10⁻⁹ M was reported but did not reach statistical significance, meaning it could plausibly be due to chance, which is worth stating plainly rather than folding into the positive findings. [1]

Cleaved caspase-3 and cleaved PARP, the two markers listed in the snapshot above, are both proteins associated with apoptosis, a normal, programmed process by which cells self-destruct in an orderly way, distinct from cell death caused by injury. A lower level of these cleaved marker proteins is generally read as a sign that fewer cells in the tissue sample were actively undergoing this self-destruction process at the time of measurement. That is a molecular-level observation about a signalling pathway inside cells, not a direct count of hairs, and it sits one interpretive step away from anything a person could see on a scalp.

The response is biphasic, meaning it moves in one direction at low doses and reverses at higher ones. Elongation, the lengthening of the growing hair shaft in culture, increased across a narrow low-concentration band and then reversed, with an 81.5% inhibition at the highest concentration tested. A large standard deviation on that figure, plus or minus 40.8%, shows substantial variability between follicles and should temper how precisely this number is read.

A standard deviation this large relative to the average means that individual follicles in the same experimental condition responded quite differently from one another; some may have been inhibited far more than 81.5%, others far less. When a reported effect carries that much spread, the single average figure is a useful summary but a poor guide to what would happen to any one follicle, let alone any one person's scalp.

Biphasic behaviour is the single most important feature of this dataset and the one most often left out of marketing summaries. It means the underlying biology does not follow a simple more-is-better pattern, and it means any attempt to translate this into an applied, real-world concentration is guesswork, because the same compound moved in opposite directions across two orders of magnitude, a hundred-fold difference in concentration.

Biologically, a biphasic curve like this often points to more than one mechanism operating at once, for example a growth-promoting signalling pathway that dominates at low concentrations, and a separate, damaging or growth-arresting effect, perhaps related to oxidative stress from excess free copper, that only becomes significant once concentration climbs high enough. The follicle study does not establish which mechanism is responsible for the inhibition seen at 10⁻⁷ M; it only establishes that the inhibition occurred and was large.

10

volunteers supplying tissue

240

follicles analysed

12 days

culture duration

81.5%

elongation inhibition at 10⁻⁷ M

HUMAN

No verified ones. A search of indexed literature does not return a controlled human clinical trial of GHK-Cu, or of the AHK-Cu variant, with hair growth or hair loss as an endpoint, meaning the specific outcome the study was designed to measure.

Claims of a clinical trial appear on product pages and in marketing material, but these do not correspond to a retrievable peer-reviewed publication and are not treated as evidence here.

REVIEW

What exists is one ex vivo (outside-the-body) organ-culture study of a related compound, plus the broader copper-peptide literature summarised in a narrative review. [1][2] An organ culture of excised follicles is closer to human biology than a single layer of cells growing flat in a dish, and it is still not a person with a scalp, a blood supply, an immune system, and the hormone environment that influences hair growth in real life.

GHK-Cu and AHK-Cu differ by a single amino acid: GHK-Cu is built from glycine, histidine, and lysine, while AHK-Cu replaces the glycine with alanine. That is a small structural change on paper, but peptide activity is often highly sensitive to exactly which amino acids are present and in what order, because the specific shape and chemical character of each amino acid side chain determines how the whole molecule folds, how tightly it holds its copper ion, and which receptors or enzymes it interacts with.

Because the two peptides are related but not identical, a finding about AHK-Cu is informative about the general class of copper-binding tripeptides, and it is a reasonable basis for further research into GHK-Cu specifically, but it is not the same as a direct finding about GHK-Cu. This distinction is the clearest example in this whole research area of language drifting from a specific, correctly labelled result to a broader, incorrect claim; the underlying data have not changed, only how they are described.

• In twelve-day human follicle organ culture, AHK-Cu increased follicle elongation across 10⁻¹² to 10⁻⁹ M and inhibited it at 10⁻⁸ M and above. [1]
• Dermal papilla cell proliferation increased over the same low-concentration window. [1]
• Apoptosis-related markers decreased at 10⁻⁹ M, while the change in the actual apoptotic-cell count was not statistically significant. [1]
• No randomised human trial establishes an effect of GHK-Cu on hair growth.
• GHK-Cu itself was not the compound tested in the principal follicle study.

Preclinical findings, meaning results from laboratory or tissue studies that come before any human testing, have been reported in follicle organ culture. Human evidence for hair outcomes remains absent, and this should not be described as hair regrowth.

Copper-peptide follicle biology is a reasonable research question with one informative dataset behind it. It is not an established hair treatment, and the accurate summary is that the question remains open pending human trials.

For the wider copper-peptide context, read What is GHK-Cu?.